Welcome to our dedicated page for Breeze Holdings Acquisition news (Ticker: BREZ), a resource for investors and traders seeking the latest updates and insights on Breeze Holdings Acquisition stock.
This news feed previously tracked announcements and developments related to Breeze Holdings Acquisition Corp (BREZ), a special purpose acquisition company that operated on the Nasdaq Capital Market. Breeze Holdings was formed as a blank check company with the objective of identifying and merging with a private operating business.
In August 2025, Breeze Holdings successfully completed its business combination with YD Biopharma Limited, a Taiwan-based biopharmaceutical company specializing in cancer diagnostics and exosome-based therapeutics. Following the merger, the combined entity began trading on Nasdaq under the new ticker symbol YDES. The merger represented the successful completion of the SPAC's mission and transitioned investors from a speculative vehicle into an operating biopharmaceutical company.
Historical news archived here covers the SPAC's formation, IPO, target identification, merger negotiations, shareholder approval process, and transaction completion. For current news and updates about the ongoing operations of the merged entity, investors should reference news feeds and disclosures associated with the ticker symbol YDES and YD Bio Limited.
The completion of this business combination marked the end of Breeze Holdings' independent existence as a publicly traded SPAC. The news timeline provides historical context for understanding how the SPAC identified its merger target, structured the transaction, and ultimately delivered the intended outcome of taking a private company public through the reverse merger process.
Breeze Holdings Acquisition Corp. (OTCQX: BRZH) shareholders have approved the business combination with YD Biopharma Limited, a Taiwan-based biopharmaceutical company focused on vaccines and therapeutic biologics. The special meeting saw 3,128,495 shares represented, with 3,127,474 shares voting in favor of the merger.
The combined entity will be renamed to YD Bio Limited and is expected to trade on the Nasdaq under the ticker symbol "YDES". The transaction is anticipated to close within two weeks, pending customary closing conditions.
Breeze Holdings Acquisition Corp (OTCQX: BRZH) has entered into a definitive agreement to merge with YD Biopharma , a clinical-stage biopharmaceutical company focusing on cancer prevention diagnostics and exosome-based therapeutics. The combined company, with an estimated enterprise value of nearly $700 million, is expected to be listed on the Nasdaq Capital Market by early 2025.
YD Biopharma has recently obtained patents, technology, and U.S. authorization for core methylation detection of pancreatic cancer, and is in the process of acquiring licenses for breast cancer detection technology. The company also specializes in ophthalmology cellular drug development and serves as a clinical testing drug supplier for Novartis.
The transaction, approved by both companies' boards, aims to provide YD Biopharma with capital to expand production and continue development, approval, and launch of new technologies. The combined company will be led by YD Biopharma's current management team.
Breeze Holdings Acquisition Corp. (OTCQX: BRZH) has announced its approval to trade on the OTCQX Best Market. The company's common stock and warrants, under tickers 'BRZH' and 'BRZHW' respectively, began trading on August 21, 2024. This update follows the termination of a previously planned business combination with TV Ammo, Inc., as reported in a Form 8-K filing on August 9, 2024.
Breeze's management team is actively pursuing a new business combination transaction and has until December 26, 2024 to complete one, as per SEC requirements. The company plans to provide further updates as progress is made in identifying a potential target company.
FAQ
What is the current stock price of Breeze Holdings Acquisition (BREZ)?
What is the market cap of Breeze Holdings Acquisition (BREZ)?
